Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26

Rhea-AI Summary

Caris Life Sciences (NASDAQ: CAI) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. A conference call and live webcast will be held at 3:30 p.m. CT (4:30 p.m. ET) to discuss the results.

Investors can join the live webcast at the provided media-server link and access a replay shortly after the call on the company's Investor Relations website.

Key Figures

Earnings report date: February 26, 2026 Earnings call time: 3:30 p.m. CT Earnings call time: 4:30 p.m. ET

3 metrics

Earnings report date February 26, 2026 Q4 and full year 2025 financial results release

Earnings call time 3:30 p.m. CT Scheduled conference call to discuss results

Earnings call time 4:30 p.m. ET Corresponding Eastern Time for the conference call

Market Reality Check

Price: $22.31 Vol: Volume 1,682,512 is below...

low vol

$22.31 Last Close

Volume Volume 1,682,512 is below the 20-day average of 2,706,870. low

Technical Shares at $22.00 are trading below the 200-day MA of $34.40 and near the 52-week low of $21.18.

Peers on Argus

CAI is up 3.53% with limited sector confirmation: peers show mixed moves, from m...

CAI is up 3.53% with limited sector confirmation: peers show mixed moves, from modest gains in HALO (+2.81%) and ROIV (+5.65%) to a decline in MRNA (-0.41%). No peers are in the momentum scanner and no same-day peer headlines are reported.

Historical Context

5 past events · Latest: 2026-01-28 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-01-28	Clinical data study	Positive	+1.9%	Real-world multiomic study on T-DXd responses and resistance in breast cancer.
2026-01-12	Preliminary earnings	Positive	-10.2%	Preliminary Q4 and 2025 results showing strong revenue growth and case volume.
2026-01-12	Commercial partnership	Positive	-10.2%	Everlywell partnership to distribute forthcoming Caris Detect MCED blood assay.
2026-01-05	Conference presentation	Neutral	-2.1%	Participation and webcast at the 44th Annual J.P. Morgan Healthcare Conference.
2025-12-19	Network expansion	Positive	+0.3%	Providence Swedish Cancer Institute joined the Caris Precision Oncology Alliance.

Pattern Detected

Recent positive corporate and financial updates have sometimes seen negative price reactions, notably on January 12, 2026 when preliminary results and a partnership coincided with a -10.21% move.

Recent Company History

Over the past few months, CAI has reported strong growth, partnerships, and data updates. Preliminary Q4 and full-year 2025 results on January 12, 2026 highlighted rapid revenue expansion, while the same day’s Everlywell partnership advanced its multi-cancer early detection strategy. Earlier, CAI announced participation at the J.P. Morgan Healthcare Conference and expansion of the Caris Precision Oncology Alliance to 99 centers. The current earnings-date announcement fits into this cadence of frequent investor communication around growth and precision oncology initiatives.

Market Pulse Summary

This announcement sets the timetable for Caris Life Sciences’ Q4 and full-year 2025 earnings on Febr...

Analysis

This announcement sets the timetable for Caris Life Sciences’ Q4 and full-year 2025 earnings on February 26, 2026, guiding when detailed financials will be available. Recent updates have highlighted strong revenue growth, expanding partnerships, and new clinical data. With shares at $22.00, below the $34.40 200-day MA and close to the $21.18 52-week low, investors may focus on how final audited results compare with January’s preliminary figures and on any forward-looking commentary during the earnings call.

AI-generated analysis. Not financial advice.

IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences^® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026.

Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.

Conference Call Details:

Date: Thursday, February 26, 2026
Time: 3:30 p.m. CT (4:30 p.m. ET)
Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4

A replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.

About Caris Life Sciences
Caris Life Sciences^® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. 

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. 

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606

Investor Relations:
IR@CarisLS.com
917.689.3511

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-302681818.html

SOURCE Caris Life Sciences

FAQ

When will Caris Life Sciences (CAI) report Q4 and full year 2025 results?

Caris will report fourth quarter and full year 2025 results on February 26, 2026. According to Caris Life Sciences, the company will present results that day and discuss them on a scheduled conference call and webcast.

What time is the Caris Life Sciences (CAI) earnings call on February 26, 2026?

The earnings call is scheduled for 3:30 p.m. CT (4:30 p.m. ET) on February 26, 2026. According to Caris Life Sciences, the company will host a live webcast simultaneously for investors and analysts.

Where can investors access the Caris Life Sciences (CAI) live webcast for the February 26 call?

Investors can access the live webcast via the provided media-server link: https://edge.media-server.com/mmc/p/49czfgs4A. According to Caris Life Sciences, the webcast will stream in real time during the 3:30 p.m. CT call.

Will a replay of the Caris Life Sciences (CAI) webcast be available after the February 26 call?

Yes. A replay of the webcast will be available shortly after the call on the company's Investor Relations website. According to Caris Life Sciences, the replay will be posted on CarisLifeSciences.com for later viewing.

What will the February 26 Caris Life Sciences (CAI) event cover?

The event will cover Caris's fourth quarter and full year 2025 financial results and related discussion. According to Caris Life Sciences, management will discuss the reported results on the conference call and live webcast.